GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » Shares Outstanding (EOP)

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Shares Outstanding (EOP) : 2.21 Mil (As of Mar. 2023)


View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. HTG Molecular Diagnostics's shares outstanding for the quarter that ended in Mar. 2023 was 2.21 Mil.

HTG Molecular Diagnostics's quarterly shares outstanding increased from Dec. 2022 (2.21 Mil) to Mar. 2023 (2.21 Mil). It means HTG Molecular Diagnostics issued new shares from Dec. 2022 to Mar. 2023 .

HTG Molecular Diagnostics's annual shares outstanding increased from Dec. 2021 (0.63 Mil) to Dec. 2022 (2.21 Mil). It means HTG Molecular Diagnostics issued new shares from Dec. 2021 to Dec. 2022 .


HTG Molecular Diagnostics Shares Outstanding (EOP) Historical Data

The historical data trend for HTG Molecular Diagnostics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics Shares Outstanding (EOP) Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.32 0.43 0.63 2.21

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.92 0.92 2.21 2.21

Competitive Comparison of HTG Molecular Diagnostics's Shares Outstanding (EOP)

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics's Shares Outstanding (EOP) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's Shares Outstanding (EOP) falls into.



HTG Molecular Diagnostics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


HTG Molecular Diagnostics  (OTCPK:HTGMQ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


HTG Molecular Diagnostics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.
Executives
Stephen Barat officer: Senior VP of Therapeutics C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc. 10 percent owner 1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy director
Byron Lawson officer: SVP/Chief Commercial Officer C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson director, officer: President & CEO
Laurence W Lytton 10 percent owner 467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski officer: VP of Accounting and Reporting C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans officer: VP, Finance & Admin. & CFO 3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen 10 percent owner HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison director